We demonstrate that CD34+ does not add benefit to the outcome of SSc patient treated with AHSCT and these findings should be further confirmed by prospective randomized trials. PubMed, Bone Marrow Transplant, 12/07/2015. (Also see Stem Cell (Bone Marrow) Transplantation)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.